Response by Elliott et al to Letter Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy"

Circ Heart Fail. 2022 Jul;15(7):e009637. doi: 10.1161/CIRCHEARTFAILURE.122.009637. Epub 2022 Jun 24.

Authors

Perry Elliott¹, Balarama Gundapaneni², Marla B Sultan³

Affiliations

¹ University College London, United Kingdom (P.E.).
² Pfizer Inc, Groton, CT (B.G.).
³ Pfizer Inc, New York, NY (M.B.S.).

PMID: 35748240
DOI: 10.1161/CIRCHEARTFAILURE.122.009637

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Amyloid Neuropathies, Familial* / drug therapy
Benzoxazoles / therapeutic use
Cardiomyopathies* / drug therapy
Heart Failure*
Humans
Prealbumin / genetics

Substances

Benzoxazoles
Prealbumin
tafamidis